Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000728388 | SCV000855955 | uncertain significance | not provided | 2017-08-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004985099 | SCV005612842 | uncertain significance | Inborn genetic diseases | 2024-08-19 | criteria provided, single submitter | clinical testing | The c.909C>G (p.N303K) alteration is located in exon 8 (coding exon 8) of the LRP4 gene. This alteration results from a C to G substitution at nucleotide position 909, causing the asparagine (N) at amino acid position 303 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005049675 | SCV005684017 | uncertain significance | Cenani-Lenz syndactyly syndrome; Sclerosteosis 2; Congenital myasthenic syndrome 17 | 2024-04-29 | criteria provided, single submitter | clinical testing |